A randomized, parallel-group, double-blind, placebo-controlled, multi-center study of Eculizumab for the prevention of delayed graft function after kidney transplantation in adult subjects at increased risk of delayed graft function
|Effective start/end date||5/20/14 → 6/1/19|
- ALEXION PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.